Behringwerke Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Behring Diagnostics Gmbh

Dade Behring Marburg Gmbh

Sanofi-aventis Pharma Deutschland Gmbh

Behringwerke Aktiengellschaft

Behrinwerke Aktienegesellschaft

Laboratoires Hoechst

Gerhard Seemann

Klaus Bosslet

Peter Pfleiderer

Cenek Kolar

Hans-Harald Sedlacek

Peter Hermentin

Hans H Sedlacek

Bernhard Auerbach

Dieter Hoffman

Jörg Czech

J&ouml;rg Czech

Gerhard Dickneite

Jean-Claude Jacquesy

Claude Monneret

Dieter Hoffmann

Michel Koch

Manfred Gerken

Jean-Pierre Gesson

Hans-Ulrich Schorlemmer

Jean-Claude Florent

Francedillaois Tillequin

Martine Mondon

Mathias Gehrmann

J Org Czech

Gilbert Gaudel

Brigitte Renoux

Beate Kehrel

Ludwig Kuhlmann

Axel Steinstr Asser

Wolfgang Dippold

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or 'humanized' MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.

Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates

The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.

Fusion proteins for prodrug activation

Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.

Monoclonal antibodies against tumor-associated antigens, processes for

The invention relates to bispecific tetravalent receptors of the formula I ##STR1## or formula II ##STR2## against a tumor-associated antigen and against an agent active against tumors.

Tetravalent bispecific receptors, the preparation and use thereof

The invention relates to monoclonal antibodies (mAB) which bind to water-soluble complexones such as ethylenediamine tetraacetate (EDTA) or diethylenetriamine pentaacetate (DTPA) with high specificity and avidity and retain their high avidity and specificity for these complexones after complexing of EDTA or DTPA with metal ions. These mAB can therefore be used, e.g. coupled on filters or other supports, for removing toxic heavy metals which are complexed with EDTA or DTPA. Furthermore, these mAB are suitable as components of immunoassays (RIA, ELISA etc.) for the quantitative determination of EDTA or DTPA in aqueous solutions.

Methods for removing heavy metals from aqueous solutions and for analysis

Monoclonal antibody against complexed and non-complexed complexing

The invention relates to the epitope which binds monoclonal antibody BW 835, DSM ACC 2022, and the use of the epitope for diagnosis and therapy.

Epitope which binds to monoclonal antibody

The invention relates to monoclonal antibodies of high avidity, which react specifically with the gangliosides GD3 and GQ1b, and to their use for detecting melanomas and other tumors or tissues expressing GD3 and GQ1b.

Monoclonal anti-ganglioside antibody and its preparation

The invention relates to monoclonal antibodies and parts thereof which bind preferentially to active human platelets, to the nucleotide sequence and amino-acid sequence of the heavy and light chain of MAb BW 2128 and to an antigen associated with thrombospondin.

Specific antibodies against activated platelets, the preparation thereof

The invention relates to polynucleotides encoding the BW 835 variable domain of an antibody against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), and expression vectors containing the polynucleotides.

Polynucleotides encoding the anti-PEM antibody BW835 variable domains

Growing community of inventors

Marburg, Germany

Gerhard Seemann